234 related articles for article (PubMed ID: 35870237)
1. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract][Full Text] [Related]
3. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
5. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
6. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
7. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
8. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
10. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
11. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
[TBL] [Abstract][Full Text] [Related]
14. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
16. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
18. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.
Lee CY; Lin Y; Bratman SV; Feng W; Kuo AH; Scheeren FA; Engreitz JM; Varma S; West RB; Diehn M
Cancer Res; 2014 Jan; 74(1):341-52. PubMed ID: 24177178
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
20. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.
Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H
BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
